REFERENCES
- Enayati PJ, Papadakis KA. Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol. 2005;39(4):303–306.
- Sukal SA, Nadiminti L, Granstein RD. Etanercept and demyelinating disease in a patient with psoriaia. J Am Acad Dermatol. 2006;54(1):160–164.
- Foeldvari I, Nielsen S, Kümmerle-Deschner J, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol. 2007;34(5):1146–1150.
- Son JH, Cha SW. Anti-TNF-alpha therapy for ankylosing spondylitis. Clin Orthop Surg. 2010;2(1):28–33.
- Toyooka K, Fujimura H. Iatrogenic neuropathies. Curr Opin Neurol. 2009;22(5):475–479.
- Lozeron P, Denier C, Lacroix C, et al. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol. 2009;66(4):490–497.
- Alshekhlee A, Basiri K, Miles JD, et al. Chronic inflammatory demyelinating polyneuropthy associated with tumor necrosis factor-alpha antagonists. Muscle Nerve. 2010;41(5):723–727.
- Mignarri A, Dotti MT, Battisti C, et al. Occurrence of ankylosing spondylitis and multiple sclerosis-like syndrome in HLA-B27 positive patient. Neurol Sci. 2009;15 [Epub ahead of print].
- Safrany E, Melegh B. Functional variants of the interleukin-23 receptor gene in non-gastrointestinal autoimmune diseases. Curr Med Chem. 2009; 16(28): 3766–3774.